103 related articles for article (PubMed ID: 21456625)
21. Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Song G; Zhu X; Li J; Hu D; Zhao D; Liao Y; Lin J; Zhang LH; Cui ZN
Bioorg Med Chem; 2017 Oct; 25(20):5709-5717. PubMed ID: 28888661
[TBL] [Abstract][Full Text] [Related]
22. Pd-mediated functionalization of polysubstituted pyrroles: their evaluation as potential inhibitors of PDE4.
Bhaskar Kumar T; Sumanth Ch; Vaishaly S; Srinivasa Rao M; Chandra Sekhar KB; Meda CL; Kandale A; Rambabu D; Rama Krishna G; Malla Reddy C; Shiva Kumar K; Parsa KV; Pal M
Bioorg Med Chem Lett; 2012 Sep; 22(17):5639-47. PubMed ID: 22871579
[TBL] [Abstract][Full Text] [Related]
23. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).
Cheung YF; Kan Z; Garrett-Engele P; Gall I; Murdoch H; Baillie GS; Camargo LM; Johnson JM; Houslay MD; Castle JC
J Pharmacol Exp Ther; 2007 Aug; 322(2):600-9. PubMed ID: 17519386
[TBL] [Abstract][Full Text] [Related]
24. Montmorillonite K-10 mediated green synthesis of cyano pyridines: Their evaluation as potential inhibitors of PDE4.
Ram Reddy T; Rajeshwar Reddy G; Srinivasula Reddy L; Jammula S; Lingappa Y; Kapavarapu R; Meda CL; Parsa KV; Pal M
Eur J Med Chem; 2012 Feb; 48():265-74. PubMed ID: 22217868
[TBL] [Abstract][Full Text] [Related]
25. Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect.
Tang L; Huang C; Zhong J; He J; Guo J; Liu M; Xu JP; Wang HT; Zhou ZZ
Eur J Med Chem; 2019 Apr; 168():221-231. PubMed ID: 30822711
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Song G; Zhao D; Hu D; Li Y; Jin H; Cui Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4610-4. PubMed ID: 26320621
[TBL] [Abstract][Full Text] [Related]
27. Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity.
Ochiai K; Ando N; Iwase K; Kishi T; Fukuchi K; Ohinata A; Zushi H; Yasue T; Adams DR; Kohno Y
Bioorg Med Chem Lett; 2011 Sep; 21(18):5451-6. PubMed ID: 21764304
[TBL] [Abstract][Full Text] [Related]
28. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
Gewald R; Grunwald C; Egerland U
Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the cellular activity of PDE 4 inhibitors using two novel PDE 4 reporter cell lines.
Wunder F; Quednau R; Geerts A; Barg M; Tersteegen A
Mol Pharm; 2013 Oct; 10(10):3697-705. PubMed ID: 23987244
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
Goto T; Shiina A; Yoshino T; Mizukami K; Hirahara K; Suzuki O; Sogawa Y; Takahashi T; Mikkaichi T; Nakao N; Takahashi M; Hasegawa M; Sasaki S
Bioorg Med Chem; 2013 Nov; 21(22):7025-37. PubMed ID: 24094436
[TBL] [Abstract][Full Text] [Related]
31. Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
Zhou ZZ; Ge BC; Zhong QP; Huang C; Cheng YF; Yang XM; Wang HT; Xu JP
Eur J Med Chem; 2016 Nov; 124():372-379. PubMed ID: 27597413
[TBL] [Abstract][Full Text] [Related]
32. Selaginpulvilins A-D, new phosphodiesterase-4 inhibitors with an unprecedented skeleton from Selaginella pulvinata.
Liu X; Luo HB; Huang YY; Bao JM; Tang GH; Chen YY; Wang J; Yin S
Org Lett; 2014 Jan; 16(1):282-5. PubMed ID: 24328835
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, biological evaluation and structural characterization of novel GEBR library PDE4D inhibitors.
Brullo C; Rapetti F; Abbate S; Prosdocimi T; Torretta A; Semrau M; Massa M; Alfei S; Storici P; Parisini E; Bruno O
Eur J Med Chem; 2021 Nov; 223():113638. PubMed ID: 34171658
[TBL] [Abstract][Full Text] [Related]
34. New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment.
Brullo C; Ricciarelli R; Prickaerts J; Arancio O; Massa M; Rotolo C; Romussi A; Rebosio C; Marengo B; Pronzato MA; van Hagen BTJ; van Goethem NP; D'Ursi P; Orro A; Milanesi L; Guariento S; Cichero E; Fossa P; Fedele E; Bruno O
Eur J Med Chem; 2016 Nov; 124():82-102. PubMed ID: 27560284
[TBL] [Abstract][Full Text] [Related]
35. Phosphodiesterase-4D Knock-down in the Prefrontal Cortex Alleviates Chronic Unpredictable Stress-Induced Depressive-Like Behaviors and Memory Deficits in Mice.
Wang ZZ; Yang WX; Zhang Y; Zhao N; Zhang YZ; Liu YQ; Xu Y; Wilson SP; O'Donnell JM; Zhang HT; Li YF
Sci Rep; 2015 Jul; 5():11332. PubMed ID: 26161529
[TBL] [Abstract][Full Text] [Related]
36. Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
Carzaniga L; Amari G; Rizzi A; Capaldi C; De Fanti R; Ghidini E; Villetti G; Carnini C; Moretto N; Facchinetti F; Caruso P; Marchini G; Battipaglia L; Patacchini R; Cenacchi V; Volta R; Amadei F; Pappani A; Capacchi S; Bagnacani V; Delcanale M; Puccini P; Catinella S; Civelli M; Armani E
J Med Chem; 2017 Dec; 60(24):10026-10046. PubMed ID: 29200281
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors.
Brullo C; Massa M; Villa C; Ricciarelli R; Rivera D; Pronzato MA; Fedele E; Barocelli E; Bertoni S; Flammini L; Bruno O
Bioorg Med Chem; 2015 Jul; 23(13):3426-35. PubMed ID: 25936260
[TBL] [Abstract][Full Text] [Related]
38. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.
Houslay MD; Adams DR
Biochem J; 2003 Feb; 370(Pt 1):1-18. PubMed ID: 12444918
[TBL] [Abstract][Full Text] [Related]
39. Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships.
Gràcia J; Buil MA; Castro J; Eichhorn P; Ferrer M; Gavaldà A; Hernández B; Segarra V; Lehner MD; Moreno I; Pagès L; Roberts RS; Serrat J; Sevilla S; Taltavull J; Andrés M; Cabedo J; Vilella D; Calama E; Carcasona C; Miralpeix M
J Med Chem; 2016 Dec; 59(23):10479-10497. PubMed ID: 27933955
[TBL] [Abstract][Full Text] [Related]
40. Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
Zhang X; Dong G; Li H; Chen W; Li J; Feng C; Gu Z; Zhu F; Zhang R; Li M; Tang W; Liu H; Xu Y
J Med Chem; 2019 Jun; 62(11):5579-5593. PubMed ID: 31099559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
